【CBS.MW纽约5月28日讯】下周，Global Signal Inc.(GSL)和Metabasis Therapeutics(MBRX)的初始股将正式上市。应指出的是，从历史传统来看，夏天是初始股市场的 ...

Metabasis的初始股预计在本周三确定最终发行价，6月3日正式上市。 Metabasis的总部位於加州圣地牙哥，主要开发治疗肝炎、肝癌和糖尿病的药物。

Metabasis Therapeutics Inc. <MBRX.O> said on Tuesday that a clinical trial of CS-917 in patients with type 2 diabetes showed the drug failed to significantly lower glycosylated hemoglobin, a ...

Metabasis Therapeutics announces the first publication on MB07811, its novel product candidate for the treatment of Hyperlipidemia ...

Metabasis can trace its roots all the way back to the founding of Gensia in 1986. After going public in 1990, Gensia suffered some setbacks with its cardiovascular drugs and reorganized.

SAN DIEGO--(BUSINESS WIRE)--Metabasis Therapeutics, Inc. (Nasdaq: MBRX), announced today the publication of four articles on MB07811, its product candidate for treating hyperlipidemia. The ...

Metabasis Therapeutics Announces CS-917 Phase 2b Clinical Trial Results and Reports on Status of Pradefovir SAN DIEGO -- Jul 17, 2007 - Metabasis Therapeutics, Inc., a biopharmaceutical company ...

Metabasis Therapeutics is reducing its workforce by 45 employees, or approximately 85%. This marks the third round of restructuring in the past six months, bringing the total number of employees ...

San Diegoâ  s Metabasis Therapeutics, a privately held biopharmaceutical company, and Whitehouse Stationâ  s Merck (NYSE: MRK) Tuesday announc ...

Metabasis originally licensed Pradefovir to Valeant Pharmaceuticals (NYSE:VRX) in 2000, which sold the rights to Schering-Plough last December for $19.2 million. Talk about good timing by Valeant.